Legal & General Group Plc Invests $1.43 Million in Core Laboratories Inc. $CLB

Legal & General Group Plc bought a new stake in shares of Core Laboratories Inc. (NYSE:CLB) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 122,575 shares of the oil and gas company’s stock, valued at approximately $1,427,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Core Laboratories by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company’s stock worth $418,000 after buying an additional 1,170 shares during the period. American Century Companies Inc. increased its position in Core Laboratories by 14.3% during the second quarter. American Century Companies Inc. now owns 133,033 shares of the oil and gas company’s stock valued at $1,533,000 after acquiring an additional 16,677 shares during the last quarter. Quantbot Technologies LP raised its stake in shares of Core Laboratories by 343.7% in the second quarter. Quantbot Technologies LP now owns 17,520 shares of the oil and gas company’s stock valued at $202,000 after acquiring an additional 13,571 shares during the period. Sei Investments Co. purchased a new stake in shares of Core Laboratories in the second quarter valued at $231,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Core Laboratories by 6.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company’s stock worth $207,000 after acquiring an additional 1,040 shares during the last quarter. Hedge funds and other institutional investors own 97.81% of the company’s stock.

Insider Activity

In other news, CEO Lawrence Bruno purchased 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average price of $10.78 per share, for a total transaction of $53,900.00. Following the completion of the purchase, the chief executive officer owned 262,438 shares in the company, valued at approximately $2,829,081.64. This represents a 1.94% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.26% of the company’s stock.

Core Laboratories Price Performance

Core Laboratories stock opened at $12.51 on Monday. The stock has a market cap of $573.96 million, a price-to-earnings ratio of 22.34, a price-to-earnings-growth ratio of 2.48 and a beta of 1.08. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.12 and a quick ratio of 1.55. Core Laboratories Inc. has a 1 year low of $9.79 and a 1 year high of $20.36. The firm has a 50-day moving average of $11.67 and a two-hundred day moving average of $13.97.

Core Laboratories (NYSE:CLB) last issued its earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $124.61 million for the quarter, compared to analyst estimates of $126.26 million. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The company’s quarterly revenue was down 4.3% compared to the same quarter last year. During the same period last year, the company posted $0.19 earnings per share. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. On average, research analysts forecast that Core Laboratories Inc. will post 0.56 earnings per share for the current year.

Core Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Monday, August 10th were issued a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Monday, August 10th. Core Laboratories’s dividend payout ratio is currently 7.14%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on CLB shares. Weiss Ratings raised shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Johnson Rice raised Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research note on Thursday, August 13th. Finally, Wall Street Zen upgraded Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Core Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

About Core Laboratories

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.